A patient's relationship with his or her doctor has long been considered an important component of healing. Now, in a novel investigation in which physicians underwent brain scans while they believed they were actually treating patients, researchers have provided the first scientific evidence indicating that doctors truly can feel their patients' pain — and can also experience their relief following treatment.


January 31, 2013 — Cardiovascular Systems Inc. (CSI) announced CONFIRM study series data presented at the 2013 International Symposium on Endovascular Therapy (ISET).
ACC AHA Electronic Health Records Clinical Management

The American College of Cardiology (ACC) and the American Heart Association (AHA) released a set of key data elements and definitions for the clinical management of patients with acute coronary syndromes (ACS) and coronary artery disease (CAD). Drafted with the primary goal of aiding data collection, the new standards should ultimately help compare data among different studies, promote the interoperability and applicability of electronic health records (EHRs) and facilitate the adoption of research to clinical practice.

Biosensors International has announced CE mark approval for its polymer-free drug-coated stent (DCS), BioFreedom.

January 31, 2013 — Belgian biotechnology company Cardio3 BioSciences (C3BS) announced it has received authorization to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European phase III trial for C3BS-CQR-1 in Belgium.

Coronary artery disease and peripheral artery disease are global health issues that affect millions of lives each year, and bioabsorbable stents are due to become the next step in treatment once the medical world has provided enough clinical data and prices are lowered, states a new report by research and consulting firm GlobalData.

January has been a month of change for Abbott, and a senior medical devices analyst from GlobalData asserts that the company’s latest cardiac diagnostics product represents the first step in a line of new diagnostic products that will act to deliver growth over the next few years.

Fujifilm Medical Systems U.S.A. Inc. shared the benefits of its zero footprint mobile application, Synapse Mobility, with visitors to the 2012 meeting of the Radiological Society of North America (RSNA). The application enables access to Fujifilm’s suite of Synapse products from hand-held devices, in addition to Macintosh- or Windows-based PCs. It was one of several Synapse products and solutions demonstrated at the show.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now